Consensus IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 01:50:50 2026-08-20 pm EDT			5-day change	1st Jan Change
545.96 ^USD	-2.89%		-3.23%	-18.91%

Aug. 17	IDEXX Laboratories, Inc. - Analyst/Investor Day
Aug. 11	IDEXX Laboratories Launches Catalyst proBNP Test for In-Clinic Cardiac Disease Assessment	MT

Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

5bdce2f2443.6n7howSYY3Az2y3-3AULW9itnaq48nTmdayJIEOc9lE.2xeg10jiGyZRgn-fnWpCL7_y2OPUh0TTLOjqDTX7uzeOG7fxYskBJF6EQg~2fde2d5daab73ab6fedaeb1e990663b3

Analysts' recommendations: IDEXX Laboratories, Inc.

Aug. 11	Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating	MT
Aug. 05	Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792	MT
Aug. 05	Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650	MT
Aug. 05	UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating	MT
Jul. 27	Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says	MT
Jul. 27	UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating	MT
Jul. 13	Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating	MT
May. 06	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655	MT
May. 06	Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785	MT
Apr. 28	UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating	MT
Apr. 27	Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating	MT
Apr. 15	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
Apr. 14	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
Mar. 31	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
Feb. 09	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
Feb. 05	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
Feb. 04	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
Feb. 03	Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830	MT
Feb. 03	UBS Adjusts IDEXX Laboratories PT to $730 From $750	MT
Feb. 03	Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785	MT
Feb. 03	BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830	MT
Feb. 03	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700	MT
Dec. 09	Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target	MT
Nov. 10	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700	MT
Nov. 04	UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

562.20USD

Average target price

698.92USD

Spread / Average Target

+24.32%

High Price Target

805.00USD

Spread / Highest target

+43.19%

Low Price Target

470.00USD

Spread / Lowest Target

-16.40%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barclays
Jefferies & Co.
Citigroup
UBS
Leerink Partners
Rothschild & Co Redburn
Stifel Nicolaus
Piper Sandler
BTIG
Morgan Stanley
JPMorgan Chase
BNP Paribas Exane
BofA Securities
Redburn Atlantic
Goldman Sachs
Atlantic Equities
Credit Suisse
Guggenheim
J.P. Morgan Chase